Curis, Inc. (CRIS): Price and Financial Metrics


Curis, Inc. (CRIS): $7.44

0.15 (+2.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRIS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

CRIS POWR Grades


  • Value is the dimension where CRIS ranks best; there it ranks ahead of 51.34% of US stocks.
  • The strongest trend for CRIS is in Momentum, which has been heading down over the past 52 weeks.
  • CRIS ranks lowest in Sentiment; there it ranks in the 1st percentile.

CRIS Stock Summary

  • Curis Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 11.69% of US listed stocks.
  • CRIS's price/sales ratio is 65.2; that's higher than the P/S ratio of 95.91% of US stocks.
  • Curis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -24.83%, greater than the shareholder yield of only 11.83% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Curis Inc are LOGC, SILC, VXRT, GSIT, and SVRA.
  • CRIS's SEC filings can be seen here. And to visit Curis Inc's official web site, go to www.curis.com.

CRIS Valuation Summary

  • In comparison to the median Healthcare stock, CRIS's price/sales ratio is 597.8% higher, now standing at 79.2.
  • CRIS's price/sales ratio has moved down 161 over the prior 243 months.
  • CRIS's EV/EBIT ratio has moved down 21.2 over the prior 243 months.

Below are key valuation metrics over time for CRIS.

Stock Date P/S P/B P/E EV/EBIT
CRIS 2021-08-31 79.2 7.2 -23.7 -21.6
CRIS 2021-08-30 76.2 6.9 -22.8 -20.7
CRIS 2021-08-27 74.8 6.8 -22.4 -20.3
CRIS 2021-08-26 71.3 6.5 -21.3 -19.3
CRIS 2021-08-25 71.9 6.5 -21.5 -19.5
CRIS 2021-08-24 70.7 6.4 -21.1 -19.1

CRIS Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at 5.76%.
  • Its 4 year price growth rate is now at -90.58%.
  • The 5 year net cashflow from operations growth rate now stands at 17.64%.
CRIS's revenue has moved up $2,362,593 over the prior 67 months.

The table below shows CRIS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 10.241 -31.43 -34.256
2021-03-31 10.315 -29.902 -30.126
2020-12-31 10.835 -25.739 -29.908
2020-09-30 11.098 -25.623 -30.999
2020-06-30 11.212 -27.628 -31.461
2020-03-31 10.946 -24.617 -31.966

CRIS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRIS has a Quality Grade of C, ranking ahead of 40.35% of graded US stocks.
  • CRIS's asset turnover comes in at 0.066 -- ranking 303rd of 681 Pharmaceutical Products stocks.
  • YMTX, VTRS, and KDNY are the stocks whose asset turnover ratios are most correlated with CRIS.

The table below shows CRIS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.066 0.950 -0.571
2021-03-31 0.085 0.950 -0.771
2020-12-31 0.135 0.951 -1.416
2020-09-30 0.291 0.951 -5.061
2020-06-30 0.301 0.951 -6.257
2020-03-31 0.287 0.952 -7.307

CRIS Price Target

For more insight on analysts targets of CRIS, see our CRIS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.00 Average Broker Recommendation 1.5 (Moderate Buy)

CRIS Stock Price Chart Interactive Chart >

Price chart for CRIS

CRIS Price/Volume Stats

Current price $7.44 52-week high $17.40
Prev. close $7.29 52-week low $1.06
Day low $7.44 Volume 102
Day high $7.44 Avg. volume 2,308,199
50-day MA $7.94 Dividend yield N/A
200-day MA $9.67 Market Cap 681.47M

Curis, Inc. (CRIS) Company Bio


Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers. The company was founded in 2000 and is based in Lexington, Massachusetts.


CRIS Latest News Stream


Event/Time News Detail
Loading, please wait...

CRIS Latest Social Stream


Loading social stream, please wait...

View Full CRIS Social Stream

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

2 Small-Cap Stocks With Substantial Upside; Raymond James Says ‘Buy’

Let’s talk a bit about return potential, and small-cap stocks. The two attributes are related, and frequently offer investors a fine combination of risk-reward ratio to emphasize the former. It’s the basic arithmetic behind finding a solid return potential. A small cap stock, one with a market value lower than $2 billion, will usually feature a relatively low share price – and when share price is low, even a small gain in absolute terms will quickly translate into a high-percentage return. Some of today’s tech giants are prime examples of the phenomenon.

Michael Marcus on TipRanks | October 18, 2021

Curis Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IRAK4 inhibitor, at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics.

Yahoo | October 7, 2021

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 106,350 shares of Curis common stock to five new employees, with a grant date of October 1, 2021 (the "Q4 2021 Inducement Grants").

Yahoo | October 6, 2021

Why Curis Stock Perked Up in August

The biotech''s shares rode the wave of buyout speculation higher last month.

The Motley Fool | September 8, 2021

Curis to Present at Upcoming Healthcare Conferences in September

No summary available.

investors Curis | September 2, 2021

Read More 'CRIS' Stories Here

CRIS Price Returns

1-mo -10.04%
3-mo -0.40%
6-mo -29.81%
1-year 530.51%
3-year 311.05%
5-year -47.61%
YTD -9.16%
2020 381.76%
2019 146.38%
2018 -80.29%
2017 -77.27%
2016 5.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8737 seconds.